Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
Infect Immun ; 69(8): 4734-41, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11447145

ABSTRACT

A promising live attenuated typhoid vaccine candidate strain for mucosal immunization was developed by introducing a deletion in the guaBA locus of pathogenic Salmonella enterica serovar Typhi strain Ty2. The resultant DeltaguaBA mutant, serovar Typhi CVD 915, has a gene encoding resistance to arsenite replacing the deleted sequence within guaBA, thereby providing a marker to readily identify the vaccine strain. CVD 915 was compared in in vitro and in vivo assays with wild-type strain Ty2, licensed live oral typhoid vaccine strain Ty21a, or attenuated serovar Typhi vaccine strain CVD 908-htrA (harboring mutations in aroC, aroD, and htrA). CVD 915 was less invasive than CVD 908-htrA in tissue culture and was more crippled in its ability to proliferate after invasion. In mice inoculated intraperitoneally with serovar Typhi and hog gastric mucin (to estimate the relative degree of attenuation), the 50% lethal dose of CVD 915 (7.7 x 10(7) CFU) was significantly higher than that of wild-type Ty2 (1.4 x 10(2) CFU) and was only slightly lower than that of Ty21a (1.9 x 10(8) CFU). Strong serum O and H antibody responses were recorded in mice inoculated intranasally with CVD 915, which were higher than those elicited by Ty21a and similar to those stimulated by CVD 908-htrA. CVD 915 also elicited potent proliferative responses in splenocytes from immunized mice stimulated with serovar Typhi antigens. Used as a live vector, CVD 915(pTETlpp) elicited high titers of serum immunoglobulin G anti-fragment C. These encouraging preclinical data pave the way for phase 1 clinical trials with CVD 915.


Subject(s)
Salmonella Vaccines/immunology , Salmonella typhi/immunology , Vaccines, Synthetic/immunology , Animals , Cell Division , Consumer Product Safety , Culture Media , Female , Genetic Engineering , Genotype , Guanine/metabolism , Mice , Mice, Inbred BALB C , Mutagenesis , Phenotype , Salmonella Vaccines/genetics , Salmonella typhi/genetics , Salmonella typhi/growth & development , Salmonella typhi/physiology , Vaccines, Attenuated/immunology , Vaccines, Synthetic/genetics
2.
Infect Immun ; 68(8): 4647-52, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10899868

ABSTRACT

Live oral Ty21a and parenteral Vi polysaccharide vaccines provide significant protection against typhoid fever, albeit by distinct immune mechanisms. Vi stimulates serum immunoglobulin G Vi antibodies, whereas Ty21a, which does not express Vi, elicits humoral and cell-mediated immune responses other than Vi antibodies. Protection may be enhanced if serum Vi antibody as well as cell-mediated and humoral responses can be stimulated. Disappointingly, several new attenuated Salmonella enterica serovar Typhi oral vaccines (e.g., CVD 908-htrA and Ty800) that elicit serum O and H antibody and cell-mediated responses following a single dose do not stimulate serum Vi antibody. Vi expression is regulated in response to environmental signals such as osmolarity by controlling the transcription of tviA in the viaB locus. To investigate if Vi antibodies can be stimulated if Vi expression is rendered constitutive, we replaced P(tviA) in serovar Typhi vaccine CVD 908-htrA with the constitutive promoter P(tac), resulting in CVD 909. CVD 909 expresses Vi even under high-osmolarity conditions and is less invasive for Henle 407 cells. In mice immunized with a single intranasal dose, CVD 909 was more immunogenic than CVD 908-htrA in eliciting serum Vi antibodies (geometric mean titer of 160 versus 49, P = 0.0007), whereas O antibody responses were virtually identical (geometric mean titer of 87 versus 80). In mice challenged intraperitoneally with wild-type serovar Typhi 4 weeks after a single intranasal immunization, the mortality of those immunized with CVD 909 (3 of 8) was significantly lower than that of control mice (10 of 10, P = 0.043) or mice given CVD 908-htrA (9 of 10, P = 0.0065).


Subject(s)
Antigens, Bacterial/immunology , Polysaccharides, Bacterial/immunology , Salmonella typhi/immunology , Typhoid Fever/prevention & control , Typhoid-Paratyphoid Vaccines/immunology , Administration, Oral , Animals , Antibodies, Bacterial/blood , Antigens, Bacterial/therapeutic use , Mice , Mice, Inbred BALB C , Polysaccharides, Bacterial/therapeutic use , Typhoid-Paratyphoid Vaccines/therapeutic use , Vaccination , Vaccines, Attenuated/immunology , Vaccines, Attenuated/therapeutic use
3.
Vaccine ; 18(21): 2193-202, 2000 Apr 28.
Article in English | MEDLINE | ID: mdl-10717338

ABSTRACT

The DeltaguaBA Shigella flexneri 2a vaccine candidate, CVD 1204, was evaluated as a delivery system for the non-toxic C-terminal of tetanus toxin (fragment C), either as a polypeptide expressed in the bacteria or as a DNA vaccine. CVD 1204 was transformed with plasmid pTETnir15 which encodes the fragment C gene (tetC) under the control of the inducible prokaryotic nir15 promoter or a DNA vaccine plasmid pcDNA3tetC which encodes tetC under the eukaryotic hCMV promoter. Guinea pigs immunised intranasally (i.n.) with either recombinant strain mounted a secretory immune response against S. flexneri 2a Lipopolysaccharide (LPS) and were protected against ocular challenge with wild-type S. flexneri 2a. Both strains were effective in eliciting a serum IgG response against fragment C in guinea pigs following i.n. immunisation. Furthermore, serum from guinea pigs immunised with CVD 1204(pTETnir15) contained tetanus toxin neutralising antibodies. These results demonstrate that this S. flexneri 2a vaccine candidate can serve as a vehicle for the delivery of foreign antigens to the systemic immune system while retaining its capacity to serve as a mucosal Shigella vaccine.


Subject(s)
Bacterial Vaccines/immunology , Peptide Fragments/immunology , Shigella flexneri/genetics , Tetanus Toxin/immunology , Vaccines, Synthetic/immunology , Administration, Intranasal , Animals , Antibodies, Bacterial/biosynthesis , Female , Lipopolysaccharides/immunology , Mice , Peptide Fragments/genetics , Plasmids , Shigella flexneri/immunology , Tetanus Toxin/genetics
4.
Infect Immun ; 68(3): 1034-9, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10678904

ABSTRACT

A phase 1 clinical trial was conducted among 35 healthy adult volunteers to evaluate the safety, immunogenicity, and shedding of different doses of CVD 1207, a live attenuated Shigella flexneri 2a vaccine candidate with specific deletion mutations in virG, sen, set, and guaBA. CVD 1207 retains the ability to invade epithelial cells but cannot effectively spread intercellularly after invasion (DeltavirG), does not produce enterotoxin (Deltasen and Deltaset), and has limited proliferation in vivo (DeltaguaBA). In a consecutive fashion, groups of three to seven subjects ingested a single oral dose of CVD 1207 at an inoculum of either 10(6), 10(7), 10(8), 10(9), or 10(10) CFU. CVD 1207 was remarkably well-tolerated at inocula as high as 10(8) CFU. In comparison, one of 12 subjects who received 10(9) CFU experienced mild diarrhea and another experienced a single episode of emesis. One of five subjects who received 10(10) CFU experienced watery diarrhea and emesis. All subjects who ingested doses of 10(8) to 10(10) CFU excreted the vaccine; in 23 of 25, the duration of excretion was

Subject(s)
Bacterial Proteins/physiology , Bacterial Toxins , Bacterial Vaccines/immunology , DNA-Binding Proteins/physiology , Enterotoxins , Escherichia coli Proteins , Shigella flexneri/immunology , Transcription Factors/physiology , Adolescent , Adult , Antibodies, Bacterial/blood , Cytokines/biosynthesis , Humans , Lymphocyte Activation , Middle Aged , Vaccines, Inactivated/immunology
5.
Clin Immunol ; 92(1): 76-89, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10413655

ABSTRACT

Attenuated Salmonella typhi strain CVD 915, harboring a deletion in guaBA that interrupts the biosynthesis of guanine nucleotides, was evaluated as a live vector vaccine for delivering foreign antigens utilizing prokaryotic or eukaryotic expression systems. Plasmids pTETnir15 and pcDNA3tetC encoding fragment C (Frag C) of tetanus toxin under the control of prokaryotic or eukaryotic promoters, respectively, were introduced into CVD 915 and administered intranasally to mice. Purified pcDNA3tetC and Frag C were given intramuscularly. High titers of serum IgG1, IgG2a, and IgG2b antibodies against Frag C were elicited by CVD 915(pTETnir15) and CVD 915(pcDNA3tetC). These responses were significantly higher than those induced by pcDNA3tetC. Proliferative responses and IL-2 and IFN-gamma production were observed in splenocytes exposed to S. typhi antigens and Frag C. We conclude that CVD 915 is a highly efficient live vector to carry foreign genes under eukaryotic or prokaryotic control and elicit potent immune responses.


Subject(s)
Bacterial Vaccines/administration & dosage , Salmonella typhi/immunology , Vaccines, Attenuated/administration & dosage , Administration, Intranasal , Animals , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Antibody Formation , Antigens, Bacterial/immunology , Cell Division , Cytokines/biosynthesis , Lymph Nodes/cytology , Mice , Recombinant Proteins/immunology , Spleen/cytology
6.
Infect Immun ; 67(2): 782-8, 1999 Feb.
Article in English | MEDLINE | ID: mdl-9916090

ABSTRACT

Based upon the lipopolysaccharide (LPS) structure and antigenicity of Shigella group B, a strategy for broad cross-protection against 14 Shigella flexneri serotypes was designed. This strategy involves the use of two S. flexneri serotypes (2a and 3a), which together bear the all of the major antigenic group factors of this group. The novel attenuated strains used in these studies were S. flexneri 2a strain CVD 1207 (DeltaguaB-A DeltavirG Deltaset1 Deltasen) and S. flexneri 3a strain CVD 1211 (DeltaguaB-A DeltavirG Deltasen). Guinea pigs were immunized with an equal mixture of these strains and later challenged (Sereny test) with a wild-type S. flexneri serotype 1a, 1b, 2b, 4b, 5b, Y, or 6 strain of demonstrated virulence in the same model. Guinea pigs that were immunized with these two vaccine strains produced serum and mucosal antibodies that cross-reacted with all the S. flexneri serotypes tested (except of S. flexneri serotype 6) as assessed by enzyme-linked immunosorbent assay, immunoblotting, and slide agglutination. Furthermore, the combination vaccine conferred significant protection against challenge with S. flexneri serotypes 1b, 2b, 5b, and Y but not with serotypes 1a, 4b, or (as predicted) 6.


Subject(s)
Bacterial Vaccines/immunology , Dysentery, Bacillary/prevention & control , Shigella flexneri/immunology , Vaccines, Synthetic/immunology , Animals , Bacterial Toxins/genetics , Bacterial Toxins/immunology , Bacterial Vaccines/genetics , Cross Reactions , Disease Models, Animal , Enterotoxins/genetics , Enterotoxins/immunology , Guinea Pigs , HeLa Cells , Humans , Lipopolysaccharides/immunology , Serotyping , Shiga Toxins , Shigella flexneri/genetics , Vaccines, Synthetic/genetics
7.
Vaccine ; 16(9-10): 1043-52, 1998.
Article in English | MEDLINE | ID: mdl-9682357

ABSTRACT

Attenuated Salmonella typhi are attractive for use as live vector vaccines to express protozoal antigens and deliver them to the human immune system. The gene encoding the mature form of Leishmania mexicana mexicana gp63 under control of tac promoter was integrated into the delta aroC locus of the chromosome of attenuated delta aroC, delta aroD S. typhi strain CVD 908. After oral immunization of BALB/c mice with two 1 x 10(9) colony forming unit doses given 21 days apart, CVD 908 omega (delta aroC::Ptac-gp63) elicited a broad T cell-mediated immune response against L. m. mexicana gp63 as demonstrated by: (1) lymphoproliferative response to fixed whole L. m. mexicana promastigotes; (2) activation of IL-2 (but not IL-4)-producing lymphocytes; (3) appearance of cytotoxic T cells against mouse mastocytoma cells expressing gp63. This T-cell mediated immune response was associated with significant protection in F1 (BALB/cXC57Bl/6) mice challenged in their footpads with a wild type strain of L. m. mexicana.


Subject(s)
Antigens, Protozoan/genetics , Leishmania mexicana/genetics , Leishmania mexicana/immunology , Metalloendopeptidases/genetics , Metalloendopeptidases/immunology , Protozoan Proteins/genetics , Protozoan Proteins/immunology , Protozoan Vaccines/genetics , Protozoan Vaccines/immunology , Salmonella typhi/genetics , Salmonella typhi/immunology , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Administration, Oral , Animals , Base Sequence , Cytotoxicity, Immunologic , DNA Primers/genetics , Genes, Protozoan , Genetic Vectors , Humans , In Vitro Techniques , Interleukin-2/biosynthesis , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/prevention & control , Lymphocyte Activation , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Protozoan Vaccines/administration & dosage , Recombinant Proteins/genetics , Recombinant Proteins/immunology , T-Lymphocytes/immunology , Vaccines, Synthetic/administration & dosage
8.
Gut ; 40(4): 505-11, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9176079

ABSTRACT

BACKGROUND: Shigella enterotoxin 1 is a novel enterotoxin elaborated by Shigella flexneri 2a that causes fluid accumulation in rabbit ileal loops and a rise in short circuit current in Ussing chambers. AIMS: To gain insights into the mechanism of action of shigella enterotoxin 1. METHODS: Supernatants from genetically engineered clones either overexpressing shigella enterotoxin 1 or producing deletion mutants of the toxin were tested in rabbit ileum both in vitro and in vivo. RESULTS: In rabbit ileum shigella enterotoxin 1 induced an irreversible rise in short circuit current that was not mediated by any of the recognised intracellular mediators of secretion. Deletion of 90% of the A subunit of the holotoxin ablated its enterotoxicity. In the in vivo perfusion model, the toxin induced a time dependent decrease in water absorption, whereas no changes were detected in the segment perfused with supernatants obtained from the deletion mutant. Finally, partially purified toxin induced a dose dependent increment in short circuit current that reached its plateau at a toxin concentration of 4 x 10(-6) M. CONCLUSIONS: Shigella enterotoxin 1 induces a time and dose dependent intestinal secretion in the rabbit animal model, suggesting that it may be responsible for the watery phase of Shigella flexneri 2a infection.


Subject(s)
Bacterial Toxins/pharmacology , Diarrhea/microbiology , Dysentery, Bacillary/metabolism , Enterotoxins/pharmacology , Ileum/drug effects , Intestinal Absorption/drug effects , Shigella flexneri/chemistry , Animals , Diarrhea/metabolism , Dose-Response Relationship, Drug , Electrophysiology , Ileum/metabolism , Ileum/physiopathology , Organ Culture Techniques , Rabbits , Time Factors , Water/metabolism
9.
Infect Immun ; 64(8): 3055-61, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8757833

ABSTRACT

Shigella flexneri 2a strain CVD 1204, which was constructed by introducing a specific, in-frame deletion mutation in the guaB-A operon, was compared with deltaaroA strain CVD 1201. CVD 1204 was less invasive for HeLa cells than CVD 1201, whereas following invasion, the abilities of the two mutants to proliferate intracellularly were similarly impaired. The reduction in invasiveness was independent of the guanine auxotrophic phenotype and fully recovered when the chromosomal deletion mutation in CVD 1204 was repaired. Following inoculation of the conjunctival sac of guinea pigs (Serény test) at high doses (10(9) CFU per eye), both strains evoked minimal, short- lived conjunctival inflammation, which was significantly milder with strain CVD 1204. Double mutant deltaguaB-A deltavirG (also called icsA) strain CVD 1205 induced, after a single intranasal dose, high mucosal immunoglobulin A antilipopolysaccharide titers, which were significantly boosted further following a second dose of vaccine given 14 days later. Upon Serény test challenge with wild-type S. flexneri 2a, CVD 1205-vaccinated animals were significantly protected against keratoconjunctivitis (zero of eight vaccinees versus five of seven controls, P = 0.03; vaccine efficacy, 100%). CVD 1205 is an attractive candidate for human clinical trials.


Subject(s)
Bacterial Vaccines/therapeutic use , Dysentery, Bacillary/prevention & control , Nasal Mucosa/immunology , Vaccines, Attenuated/therapeutic use , Vaccines, Synthetic/therapeutic use , Administration, Intranasal , Animals , Antibodies, Bacterial/immunology , Bacterial Proteins/genetics , Base Sequence , DNA-Binding Proteins/genetics , Genetic Engineering , Guinea Pigs , HeLa Cells , Humans , Immunoglobulin A/biosynthesis , Molecular Sequence Data , Safety , Sequence Deletion , Shigella flexneri/classification , Shigella flexneri/immunology , Shigella flexneri/pathogenicity , Transcription Factors/genetics
10.
Infect Immun ; 64(1): 23-7, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8557344

ABSTRACT

The use of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a live vector for enterotoxigenic Escherichia coli (ETEC) antigens is reported. CVD 1203 alone or expressing colonization factor antigen fimbriae and CS3 fibrillae of ETEC was given to guinea pigs and mice, orogastrically (o.g.) or intranasally (i.n.). CVD 1203 given i.n. elicited high titers of antilipopolysaccharide (anti-LPS) immunoglobulin A (IgA) and was protective in guinea pigs against a homologous conjunctival challenge. Whereas a strong IgA response against colonization factor antigen CS3, and Shigella LPS was detected in tears and serum of guinea pigs after o.g. or i.n. immunization, the i.n. route elicited significantly higher antibody titers. A strong serum IgG response was also observed against the ETEC antigens, although no serum anti-LPS IgG response was detected. The immune response in mice followed a pattern similar to that in guinea pigs, and the difference between the responses after o.g. and i.n. administration was even more remarkable.


Subject(s)
Alkyl and Aryl Transferases , Antigens, Bacterial/immunology , Bacterial Vaccines/immunology , Dysentery, Bacillary/prevention & control , Escherichia coli Infections/prevention & control , Escherichia coli/immunology , Fimbriae Proteins , Shigella flexneri/immunology , 3-Phosphoshikimate 1-Carboxyvinyltransferase , Animals , Antigens, Bacterial/genetics , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Bacterial Vaccines/administration & dosage , Bacterial Vaccines/genetics , DNA-Binding Proteins/genetics , Drug Administration Routes , Gastric Mucosa/immunology , Guinea Pigs , Immunoglobulin A/analysis , Immunoglobulin A/blood , Immunoglobulin G/blood , Immunologic Tests , Mice , Mouth Mucosa/immunology , Nasal Mucosa/immunology , Sequence Deletion , Shigella flexneri/genetics , Transcription Factors/genetics , Transferases/genetics , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology
11.
J Infect Dis ; 172(5): 1408-10, 1995 Nov.
Article in English | MEDLINE | ID: mdl-7594690

ABSTRACT

Shigella enterotoxin 1 (ShET1) is a novel, iron-dependent, toxin encoded by chromosomal genes (set1). To determine the prevalence of this enterotoxin, 172 Shigella clinical isolates (and 10 enteroinvasive Escherichia coli [EIEC]) from distant areas worldwide, representing all 4 groups and 45 serotypes of Shigella, were screened for set1 by DNA colony hybridization and polymerase chain reaction amplification. set1 was present in all 22 Shigella flexneri 2a strains tested but was rare in isolates of other Shigella serotypes (3.3%, 5/150) and not found in EIEC (0/10). That ShET1 is found almost exclusively in S. flexneri 2a may help explain the epidemiologic predominance of this serotype in the developing world.


Subject(s)
Bacterial Toxins/genetics , Dysentery, Bacillary/microbiology , Enterotoxins/genetics , Genes, Bacterial , Shigella/classification , Shigella/isolation & purification , Bacterial Toxins/biosynthesis , Base Sequence , DNA Primers , Diarrhea/microbiology , Escherichia coli/classification , Escherichia coli/genetics , Humans , Molecular Sequence Data , Oligonucleotide Probes , Polymerase Chain Reaction , Serotyping , Shiga Toxins , Shigella/genetics
12.
J Clin Invest ; 95(6): 2853-61, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7769126

ABSTRACT

Culture filtrates of Shigella flexneri 2a strain M4243 grown in iron-depleted medium, caused significant fluid accumulation in rabbit ileal loops. Also, when tested in Ussing chambers, a greater rise in potential difference and short circuit current was seen with such filtrates compared with the medium control. Analogous filtrates from two M4243 derivatives lacking the 140-MD invasiveness plasmid (either M4243avir or BS103) retained 60-65% of the wild-type enterotoxic activity. Ultrafiltration and gel exclusion size fractionation of M4243 filtrate revealed that the activity was approximately 60 kD. SDS-PAGE performed on this fraction showed 18 bands, 5 of which reacted with human convalescent sera. Genes encoding this enterotoxin, named ShET1 for Shigella enterotoxin 1, were cloned from the S. flexneri 2a chromosome, and two separate open reading frames of 534 and 186 bp were sequenced. These observations suggest that S. flexneri 2a elaborates two distinct enterotoxins: ShET1, encoded by genes located on the chromosome, and ShET2, encoded by a gene on the 140-MD invasiveness plasmid. ShET1, which is composed of two distinct subunits and is elaborated in vivo, where it elicits an immune response, may be important in the pathogenesis of diarrheal illness due to S. flexneri 2a.


Subject(s)
Enterotoxins/genetics , Shigella flexneri/pathogenicity , Amino Acid Sequence , Animals , Base Sequence , Cloning, Molecular , Enterotoxins/pharmacology , Genes, Bacterial , Intestine, Small/drug effects , Male , Molecular Sequence Data , Rabbits , Shigella flexneri/genetics
13.
Infect Immun ; 62(11): 5168-72, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7927802

ABSTRACT

We engineered an oral Shigella vaccine prototype that can invade intestinal epithelial cells but cannot undergo extensive intracellular replication or extend to adjacent epithelial cells. Strain CVD 1203, derived from wild-type Shigella flexneri 2a by introducing deletions in chromosomal aroA and invasion plasmid virG, was highly attenuated in the Sereny test. Two 10(9)-CFU orogastric doses (2 weeks apart) stimulated production of secretory immunoglobulin A antibodies to S. flexneri 2a and protected against conjunctival sac challenge with virulent S. flexneri 2a.


Subject(s)
Bacterial Vaccines/immunology , Shigella flexneri/immunology , Vaccines, Attenuated/immunology , Administration, Oral , Animals , Bacterial Vaccines/administration & dosage , Base Sequence , DNA Primers , Gene Deletion , Genes, Bacterial , Guinea Pigs , HeLa Cells/microbiology , Humans , Immunoglobulin A, Secretory/immunology , Keratoconjunctivitis/prevention & control , Molecular Sequence Data , Plasmids , Shigella flexneri/genetics , Shigella flexneri/growth & development , Shigella flexneri/pathogenicity , Vaccines, Attenuated/administration & dosage
14.
J Infect Dis ; 169(4): 927-31, 1994 Apr.
Article in English | MEDLINE | ID: mdl-8133113

ABSTRACT

rcsp, encoding amino acids 21-398 of Plasmodium falciparum circumsporozoite protein (CSP), under control of tacP was integrated into the chromosomal delta aroC locus of attenuated delta aroC, delta aroD Salmonella typhi CVD 908. By immunoblot and ELISA, rCSP expression was greater from a multicopy plasmid than from the single chromosomal gene. CVD 908 omega (delta aroC1019::tacP-rcsp) was well tolerated by 10 volunteers who were fed two doses of 5 x 10(7) organisms 8 days apart. Seven subjects excreted the vaccine strain for 1-3 days. All subjects developed serologic responses to O and H antigens of the live vector, whereas 3 vaccinees responded to the foreign antigen: 1 developed an 80-fold rise in serum anti-sporozoite antibody, another had a 4-fold rise in antibody to a recombinant portion of CSP (residues 309-345), while a third vaccinee developed CSP-specific CD8+ cytotoxic T lymphocyte activity. This is the first report of attenuated S. typhi eliciting a human serologic or a cytotoxic T lymphocyte response to a foreign protein. Improved foreign gene expression should enhance immunogenicity.


Subject(s)
Malaria Vaccines , Plasmodium falciparum/immunology , Protozoan Proteins/genetics , Salmonella typhi/genetics , Administration, Oral , Adult , Amino Acid Sequence , Animals , Antibodies, Protozoan/biosynthesis , Base Sequence , Cloning, Molecular , DNA Primers/chemistry , Female , Gene Expression Regulation , Genetic Vectors , Humans , Malaria Vaccines/administration & dosage , Malaria Vaccines/adverse effects , Malaria Vaccines/immunology , Mice , Molecular Sequence Data , Protozoan Proteins/chemistry , Protozoan Proteins/immunology , Protozoan Vaccines , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/immunology
16.
J Parasitol ; 74(3): 495-9, 1988 Jun.
Article in English | MEDLINE | ID: mdl-3379531

ABSTRACT

We describe here a new tissue culture method for prolonged laboratory maintenance of tachyzoites of the highly virulent RH strain of Toxoplasma gondii. Using a rapidly proliferating murine tumor cell line (YAC-1), the method described is easy to perform and is as or more efficient (both in terms of yield and cost) than other traditional methods for maintenance of the parasite. Furthermore, upon prolonged maintenance (greater than 160 days) in YAC-1 tissue culture, the pathogenicity of the parasite, as well as its capacity to elicit an immune response, are comparable to that of organisms maintained in mice. We conclude therefore, that the method described herein is a suitable alternative to the traditional method of maintenance of virulent RH strain T. gondii tachyzoites.


Subject(s)
Toxoplasma/growth & development , Animals , Costs and Cost Analysis , Macrophages/parasitology , Methods , Mice , Toxoplasma/pathogenicity , Tumor Cells, Cultured/parasitology
SELECTION OF CITATIONS
SEARCH DETAIL
...